Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Above 50-Day Moving Average – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $9.71 and traded as high as $10.04. Astellas Pharma shares last traded at $9.99, with a volume of 80,077 shares traded.

Astellas Pharma Stock Down 0.1 %

The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. The business’s 50-day simple moving average is $9.71 and its 200-day simple moving average is $10.48. The company has a market capitalization of $18.09 billion, a PE ratio of -45.43 and a beta of 0.29.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share (EPS) for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. As a group, equities research analysts anticipate that Astellas Pharma Inc. will post 0.42 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.